<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0012115'>Hepatitis</z:hpo> B <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> is a serious health problem in endemic areas particularly among immunocompromised patients </plain></SENT>
<SENT sid="1" pm="."><plain>The more profound immunosuppression in recipients of hematopoietic stem cell transplantations (HCT) can lead to more complicated <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B virus (HBV)-related events </plain></SENT>
<SENT sid="2" pm="."><plain>Despite the high risk of recipient <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> allogeneic HCT donors with HBV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> are not excluded in the absence of an alternative donor </plain></SENT>
<SENT sid="3" pm="."><plain>A 25 year-old man with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> underwent allogeneic HCT from his HLA-identical sibling </plain></SENT>
<SENT sid="4" pm="."><plain>The patient was <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B naive and had <z:mpath ids='MPATH_458'>normal</z:mpath> liver function tests </plain></SENT>
<SENT sid="5" pm="."><plain>However the donor had <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B surface antigen (HbsAg) positivity, and collected stem cells were positive for HBV DNA (1 × 10(4) copies/mL) </plain></SENT>
<SENT sid="6" pm="."><plain>Lamivudine was initiated to treat the patient prior to transplantation </plain></SENT>
<SENT sid="7" pm="."><plain>Forty days after the HCT, the patient displayed <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B surface antibody (HBsAb), <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B core antibody (HBcAb), and <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B e antibody (HBeAb), with HBV-DNA negativity </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> was tapered and finally stopped at day + 256 </plain></SENT>
<SENT sid="9" pm="."><plain>On day +368, 112 days after the cessation of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> HBV reactivation was detected with an HBV-DNA level of 10 × 10(4) copies/mL despite lamivudine </plain></SENT>
<SENT sid="10" pm="."><plain>After demonstration of the YMDD mutation, adefovir dipivoxil was combined with lamivudine </plain></SENT>
<SENT sid="11" pm="."><plain>The HBV-DNA became negative; AST ALT levels decreased to <z:mpath ids='MPATH_458'>normal</z:mpath> levels after a month of combination therapy </plain></SENT>
<SENT sid="12" pm="."><plain>In conclusion adefovir was effective to treat lamivudine-resistant HBV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in an allogeneic HCT recipient </plain></SENT>
</text></document>